Bristol-Myers Squibb (BMY) closed at $56.95 in the latest trading session, marking a -0.19% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.36%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq added 0.15%.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. On that day, BMY is projected to report earnings of $1.46 per share, which would represent year-over-year growth of 23.73%. Meanwhile, our latest consensus estimate is calling for revenue of $9.96 billion, up 58.78% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.14 per share and revenue of $41.58 billion, which would represent changes of +30.92% and +59.03%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BMY. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% higher. BMY currently has a Zacks Rank of #2 (Buy).
In terms of valuation, BMY is currently trading at a Forward P/E ratio of 9.29. Its industry sports an average Forward P/E of 15.1, so we one might conclude that BMY is trading at a discount comparatively.
It is also worth noting that BMY currently has a PEG ratio of 1.11. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 15, putting it in the top 6% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BristolMyers Squibb Company (BMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research